SLC5A2 and diabetes mellitus: As SGLT2 inhibitors confer clinical cardiovascular benefits in heart failure patients with or without diabetes (McMurray et al., 2019; Nassif et al., 2019), we next examined whether EMPA reduced cardiac damage in LAD ligation-operated WT mice (n = 75 WT 10–12 week mice) (Fig. S2A).